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Pancreatic cancer desmoplasia is thought to confer biological aggressiveness. In this issue of Cancer Cell,
O¨zdemir and colleagues and Rhim and colleagues demonstrate that targeting the stroma results in undiffer-
entiated, aggressive pancreatic cancer that responds to checkpoint blockade or antiangiogenic therapy,
uncovering a protective role by stroma in this cancer.Pancreatic ductal adenocarcinoma
(PDAC) has a dismal 5-year survival rate
of 6% and is projected to be the second
leading cause of cancer death by 2030
(Rahib et al., 2014). PDACs harbor high-
frequency mutations in major cancer
driver genes, including KRAS (95%),
CDKN2A (95% mutated and 5%
epigenetically silenced), TP53 (75%),
and SMAD4 (55%), numerous low-
frequency driver mutations, and regions
of hypermutation termed kataegis (Alex-
androv et al., 2013). There is also over-
expression of growth factors, their high
affinity tyrosine kinase receptors, TGF-b
isoforms, and sonic hedgehog (Shh), as
well as loss of negative growth constraints
(Whipple and Korc, 2008).
PDACs exhibit desmoplasia, which
derive from pancreatic stellate cells that
are activated to proliferate and produce
collagens, laminin, and fibronectin (Apte
et al., 2013). Consequently, the tumor
microenvironment exhibits enhanced
stiffness (elastic modulus), increased hy-
aluronic acid content, and elevated hydro-
static pressures that may blunt effective
intratumoral drug delivery (Provenzano
et al., 2012). The stroma is also believed
to contribute to tumor hypoperfusion and
hypoxia and harbor infiltrative macro-
phages and inflammatory cells with the
potential to suppress cancer-directed
immune mechanisms. In theory, there-
fore, stroma depletion could enhance
drug delivery to the cancer cells within
the tumor mass while disrupting delete-
rious stroma-cancer cell interactions.
Genetically engineered mouse models
(GEMMs) of PDAC have transformed our
understanding of PDAC pathobiology,
yielding novel information regarding
potential therapeutic targets (Guerra and
Barbacid, 2013). These autochthonousmodels recapitulate events occurring in
human PDAC, including pancreatic
intraepithelial neoplasia (PanIN), pro-
gression to murine PDAC (mPDAC),
acinar-to-ductal metaplasia (ADM), abun-
dant stroma, inflammatory changes, and
metastasis in the context of an intact
immune system. Despite its success in
GEMMs, stroma-targeting clinical trials
have failed. In this issue of Cancer Cell,
O¨zdemir et al. (2014) and Rhim et al.
(2014) used two distinct strategies to
address the root cause for this failure.
O¨zdemir et al. (2014) targeted aSMA+
myofibroblasts by crossing Ptflacre/+;
KrasLSL-G12D/+;Tgfbr2flox/flox (KTC) mice
with aSMA-tk transgenic mice and
administering ganciclovir (GCV) to the
resultant KTC;aSMA-tk mice at PanIN
(early) or mPDAC (late) stages. Remark-
ably, myofibroblast depletion at either
stage yielded undifferentiated and inva-
sive tumors with necrotic regions; both
groups succumbed earlier than mice
not receiving GCV. Similar results were
obtained in Pdx1cre/+;KrasLSL-G12D/+;
Trp53R172H/+ (KPC) mice crossed with
aSMA-tk mice, confirming that desmo-
plasia protects the host.
O¨zdemir et al. (2014) also showed that
key concepts regarding the deleterious
effects of stroma in PDAC need to be
revamped. Thus, myofibroblast depletion
led to decreased elastic modulus without
improving gemcitabine’s therapeutic ac-
tions or altering hyaluronic acid content,
as determined by assaying for its marker
hyaluronic acid binding protein. Crossing
KTC mice with Cre-reporter mice and
depleting aSMA+ cells revealed that
reporter-positive cancer cells exhibited
increased epithelial-to-mesenchymal
transition (EMT), elevated expression of
pro-EMT transcription factors (Twist,Cancer CellSnail, and Slug), a stem cell-like pheno-
type (with increased CD44+CD133+ cell
populations), in vitro sphere formation,
and in vivo tumorigenicity. Myofibroblast
depletion at either the PanIN or mPDAC
stage attenuated tumor angiogenesis
without altering glycolysis and enhanced
tumor hypoxia, which was determined
by staining for pimonidazole adduct
formation. Moreover, expression profiling
revealed that CAFs exhibited ECM re-
modeling and a proangiogenic profile in
contrast to normal pancreas fibroblasts.
Myofibroblast depletion was also asso-
ciated with altered immune gene expres-
sion and changed infiltrating immune cell
populations, specifically decreased CD4+
effector T cells, increased CD4+Foxp3+
regulatory T cells (Tregs), and decreased
cytotoxic CD8+/Treg and CD3+/CD11b+
ratios. Importantly, Ctla4 expression was
increased. Treatment of myofibroblast-
depleted mice with a CLTA-4 blocking
antibody attenuated PDAC progression,
improved overall survival, induced tumor
clearance in up to 25% of the pancreas,
and reprogrammed the transcriptome to
a pattern that resembled control (myofi-
broblast-competent) tumors.
Rhim et al. (2014) chose to delete
Shh in the cancer cells to suppress
mPDAC stroma. Accordingly, they
crossed Pdx1-Cre;KrasLSL-G12D/+;p53fl/+;
Rosa26 LSL-YFP/+ (KPfl/+CY) mice with
Shhfl/fl mice, generating ShhKPfl/+CY
mice. These mice exhibited decreased
Gli1 expression and stroma formation.
Although Shh deletion per se did not alter
pancreatic development, by comparison
with KPfl/+CY mice, ShhKPfl/+CY mice
had more frequent PanIN and ADM
lesions at a young age, an earlier appear-
ance of mPDAC that was more undiffer-
entiated, and increased metastasis; the25, June 16, 2014 ª2014 Elsevier Inc. 711
Figure 1. Deleterious Consequences of Targeting the Stroma in Pancreatic Cancer
(A) Highly desmoplastic PDAC. These tumors exhibit activated cancer-associated fibroblasts (CAFs) that
synthesize and release collagens, laminin, and fibronectin (desmoplasia); are infiltrated by various inflam-
matory cells including macrophages (Macs); and produce excess growth factors and cytokines. Cancer
cells in these lesions may be well, moderately, or poorly differentiated.
(B) Stroma-depleted PDAC. Engineered myofibroblast (MFB) depletion, genetic deletion of sonic hedge-
hog (Shh), or Smoothened receptor targeting with IPI-926 were used to dramatically decrease the pres-
ence of MFBs and CAFs in several genetically-engineered mouse models (GEMMs) of PDAC. Each of
these strategies yielded undifferentiated PDAC, enhanced EMT, increased pancreatic cancer cell prolif-
eration, and altered immune cell infiltrate profiles. Direct MFB depletion was associated with attenuated
angiogenesis and an increased response to immune checkpoint blockade with an anti-CTLA-4 antibody.
Shh deletion or IPI-296 treatment was associated with increased angiogenesis (Endo) and metastasis, a
greater incidence of cachexia, and increased responsiveness to DC101, which targets VEGFR2. Thus, in
several GEMMs and with different strategies, targeting the stroma unmasks a previously unrecognized
protective effect in PDAC.
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Previewsmice also died more rapidly. In this
context, pancreatic cancer cells (PCCs)
showed enhanced proliferation and
angiogenesis, increased Zeb1 and Slug
expression consistent with EMT, and
reduced CD45+ myeloid cells and F4/80+
monocytes infiltration. Similar results
were observed when KPC mice were
treated with IPI-926, a Smoothened inhib-
itor. Thus, genetic Shh deletion or phar-
macological targeting of Shh signaling
pathways attenuates stroma formation
and leads to more aggressive mPDAC.
KPC mice typically die due to locally
invasive disease, extensive metastases,
or marked cachexia. This course was not
altered by gemcitabine treatment and
was worsened by added treatment with
IPI-926, most notably because of faster
onset of severe cachexia, which also
occurred in a subset of control ShhKPfl/+
CY mice that were not treated with IPI-
926. PanIN and ADM lesions were also
increased by IPI-926 treatment, and this
effect was partially prevented by gemcita-
bine treatment. These findings suggest
that the actions of IPI-296 in promoting
cachexia are due to its effects on mPDAC
aggressiveness and that gemcitabine
may be effective at attenuating precursor
lesion progression to PDAC. Given
that patients with PDAC often develop
cachexia (Fearon et al., 2011), it will be
important to determine whether cachexia
correlates with attenuated stroma and712 Cancer Cell 25, June 16, 2014 ª2014 Elsenhanced tumor angiogenesis and to
delineate the mechanisms whereby
stroma protects against cachexia.
Rhim et al. (2014) proposed that
mesenchymal stromal cells exert an
antiangiogenic effect on endothelial cells,
which contrasts with the finding by
O¨zdemir et al. (2014) that CAFs express
proangiogenic factors. Rhim et al. (2014)
also targeted VEGFR2 signaling with the
blocking antibody DC101, which pro-
longed the survival of ShhKPfl/+CY mice,
but not KPfl/+CY mice, even though
mPDAC VEGF expression was similar in
both groups. The authors suggest that
stroma depletion leads to greater depen-
dence on VEGF rather than its further
induction and demonstrates that undiffer-
entiated PDAC in patients is associated
with enhanced tumor angiogenesis and
decreased stroma.
Taken together (Figure 1), these
two paradigm-changing studies provide
important new insights on PDAC pathobi-
ology: (1) the stroma inPDAC is protective,
and this protective action is potentially
already exerted at the PanIN stage; (2) tar-
geting the stroma can lead to a more bio-
logically aggressive form of PDAC with
enhanced PCC proliferation, but can also
‘‘prime’’ the tumor to more efficiently
respond to checkpoint blockade and
to antiangiogenic therapy; and (3) while
many aspects of stromal biology are still
valid, it is important to reassess variousevier Inc.therapeutic approaches in light of the cur-
rent findings, and more specifically target
the cancer cells and not the stromal cells
while bearing in mind that the actions of
the stroma in PDAC may be context
dependent. Although the concepts of a
protective stroma and targeting angio-
genesis in PDAC are not novel, we now
haveabetter understandingof their poten-
tial roles, which may allow for improved
precision therapy. Moreover, given the
complexity and plasticity of the stroma
and associated immune cells, further
studies are necessary to more clearly
delineate deleterious and beneficial as-
pects of stroma biology in PDAC. Finally,
because oncogenic Kras may induce
PanIN-associated stroma, we also need
to study the pathways that allow PanIN
and ultimately PCCs to bypass the protec-
tive effects of the stroma.ACKNOWLEDGMENTS
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